What Next After A Year Of Innovation And Growth?
As part of its ‘Pharma Outlook for 2022’, leading healthcare publication, In Vivo, explored the outlook for US and EU venture capital funding in biopharma. Asking whether the sector can keep the momentum going for investments, it drew on the experience and insight of prominent investors [many among them our clients,] to provide comment on […]